The relationship between visfatin, resistin and CRP parameters and insulin resistance in obese and non-obese type 2 diabetic individuals

Year 2025, EARLY ONLINE, 1 - 13

Arzu Yüksel , Ayşe Gül Sündüs Telci , Ayşe Kubat Üzüm

https://doi.org/10.18621/eurj.1537714

Abstract

Objectives: Inflammation caused by adipokines such as adiponectin, leptin, resistin, visfatin, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) released by fat cells and immune cells within fat tissue is a significant factor in the onset of insulin resistance and Type 2 diabetes mellitus (T2DM). This study explores the relationship among these adipokines and insulin resistance in T2DM patients, focusing on the impact of abdominal obesity.

Methods: The study involved 73 adult T2DM patients who were seperated into two groups based on their body mass index (BMI): 47 were classified as obese (BMI ≥30 kg/m²), and 26 were classified as non-obese (BMI <25 kg/m²). Additionally, 42 healthy controls were included, comprising 18 obese and 24 non-obese individuals. Adipokine concentrations (resistin, leptin, adiponectin, visfatin, IL-6 and TNF-α) were measured with the ELISA method.

Results: The concentrations of adiponectin were substantially lower in T2DM patients relative to the control group (P<0.0125). Leptin concentrations did not show significant differences between the groups, but there was a notable increase in obese controls compared to non-obese controls (P<0.0125). TNF-α concentrations were significantly higher in obese controls than in non-obese controls (P<0.001). Resistin concentrations were significantly correlated with C-reactive protein (CRP) and IL-6 in both groups, independent of BMI (P=0.001 and P<0.0125, respectively). We found that CRP levels were significantly higher in both obese diabetics compared to non-obese diabetics and in obese controls compared to non-obese controls (P<0.0001).

Conclusions: Adipose tissue is a crucial determinant of circulating inflammation markers. Elevated CRP concentrations in obesity may result from insulin resistance rather than being a cause. Further research is required to comprehend the connection between fatty tissue, insulin resistance, and elevated inflammatory markers.

Keywords

Obesity, type 2 diabetes mellitus, resistin, visfatin, adiponectin, leptin

Ethical Statement

This study follows the principles of the Declaration of Helsinki. The study was conducted with approval from Istanbul University Faculty of Medicine Clinical Research Ethics Committee dated 28.08.2006 and numbered 1745. All participants provided their informed consent.

References

• 1. Kanaley JA, Colberg SR, Corcoran MH, et al. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2022;54(2):353-368. doi: 10.1249/MSS.0000000000002800.
• 2. Asghar S, Asghar S, Mahmood T, Bukhari SMH, Mumtaz MH, Rasheed A. Microalbuminuria as the Tip of Iceberg in Type 2 Diabetes Mellitus: Prevalence, Risk Factors, and Associated Diabetic Complications. Cureus. 2023;15(8):e43190. doi: 10.7759/cureus.43190.
• 3. Obradovic M, Sudar-Milovanovic E, Soskic S, et al. Leptin and Obesity: Role and Clinical Implication. Front Endocrinol (Lausanne). 2021;12:585887. doi: 10.3389/fendo.2021.585887.
• 4. Kim JY, Bacha F, Tfayli H, Michaliszyn SF, Yousuf S, Arslanian S. Adipose Tissue Insulin Resistance in Youth on the Spectrum From Normal Weight to Obese and From Normal Glucose Tolerance to Impaired Glucose Tolerance to Type 2 Diabetes. Diabetes Care. 2019;42(2):265-272. doi: 10.2337/dc18-1178. Epub 2018 Nov 19.
• 5. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34(1):2-11. doi: 10.1016/j.diabet.2007.09.004.
• 6. Jang DI, Lee AH, Shin HY, et al. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. Int J Mol Sci. 2021;22(5):2719. doi: 10.3390/ijms22052719.
• 7. Tang YH, Wang YH, Chen CC, Chan CJ, Tsai FJ, Chen SY. Genetic and Functional Effects of Adiponectin in Type 2 Diabetes Mellitus Development. Int J Mol Sci. 2022;23(21):13544. doi: 10.3390/ijms232113544.
• 8. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J. 2020;287(15):3141-3149. doi: 10.1111/febs.15322.
• 9. Huang YL, Chen YL, Lin JD, et al. Visfatin and Retinol Binding Protein-4 in Young-Onset Type 2 Diabetes Mellitus. Medicina (Kaunas). 2023;59(7):1278. doi: 10.3390/medicina59071278.
• 10. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev. 2011;27(6):515-527. doi: 10.1002/dmrr.1201.
• 11. Polidori N, Mainieri F, Chiarelli F, Mohn A, Giannini C. Early Insulin Resistance, Type 2 Diabetes, and Treatment Options in Childhood. Horm Res Paediatr. 2022;95(2):149-166. doi: 10.1159/000521515.
• 12. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020.
• 13. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350(7):664-671. doi: 10.1056/NEJMoa031314.
• 14. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45(5):633-638. doi: 10.2337/diab.45.5.633.
• 15. Gan SK, Kriketos AD, Poynten AM, et al. Insulin action, regional fat, and myocyte lipid: altered relationships with increased adiposity. Obes Res. 2003;11(11):1295-305. doi: 10.1038/oby.2003.176.
• 16. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813-823. doi: 10.2337/diacare.27.3.813.
• 17. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5(1):70-75. doi: 10.1007/s11892-005-0071-7.
• 18. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649-1652. doi: 10.1016/s0140-6736(99)01046-6.
• 19. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-234. doi: 10.1001/jama.286.3.327.
• 20. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548-2556. doi: 10.1210/jc.2004-0395.
• 21. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'? Curr Diabetes Rev. 2006;2(2):195-211. doi: 10.2174/157339906776818532.
• 22. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-1935. doi: 10.1210/jcem.86.5.7463.
• 23. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53(9):2473-2478. doi: 10.2337/diabetes.53.9.2473.
• 24. Nogueiras R, Wilson H, Rohner-Jeanrenaud F, Tschöp MH. Central nervous system regulation of adipocyte metabolism. Regul Pept. 2008;149(1-3):26-31. doi: 10.1016/j.regpep.2007.09.034.
• 25. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371-379. doi: 10.1038/nri1350.
• 26. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334(5):292-295. doi: 10.1056/NEJM199602013340503.
• 27. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-4200. doi: 10.1210/jcem.82.12.4450.
• 28. Maachi M, Piéroni L, Bruckert E, et al. Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women. Int J Obes Relat Metab Disord. 2004;28(8):993-997. doi: 10.1038/sj.ijo.0802718.
• 29. Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002;87(5):2084-2089. doi: 10.1210/jcem.87.5.8450.
• 30. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87-91. doi: 10.1126/science.7678183.
• 31. Rush EC, Plank LD, Yajnik CS. Interleukin-6, tumour necrosis factor-alpha and insulin relationships to body composition, metabolism and resting energy expenditure in a migrant Asian Indian population. Clin Endocrinol (Oxf). 2007;66(5):684-690. doi: 10.1111/j.1365-2265.2007.02801.x.
• 32. Zavaroni I, Numeroso F, Dongiovanni P, et al. What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers? Metabolism. 2003;52(12):1593-1596. doi: 10.1016/s0026-0495(03)00329-9.
• 33. Hivert MF, Sullivan LM, Fox CS, et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab. 2008;93(8):3165-3172. doi: 10.1210/jc.2008-0425.
• 34. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation, and disease. FEBS J. 2020;287(15):3141-3149. doi: 10.1111/febs.15322.
• 35. Curat CA, Wegner V, Sengenès C, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006;49(4):744-747. doi: 10.1007/s00125-006-0173-z.
• 36. Fukuhara A, Matsuda M, Nishizawa M, Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307(5708):426-430. doi: 10.1126/science.1097243.
• 37. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab. 2006;91(3):1181-1184. doi: 10.1210/jc.2005-1395.
• 38. Arner P. Visfatin--a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(1):28-30. doi: 10.1210/jc.2005-2391.
• 39. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-674. doi: 10.1161/01.cir.0000055188.83694.b3.
• 40. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'? Curr Diabetes Rev. 2006;2(2):195-211. doi: 10.2174/157339906776818532.